Abstract
Adjuvant chemotherapy especially fluoropyrimidines combinations with oxaliplatin has reduced the risk of tumor recurrence and improved survival for patients with resected colon cancer and becomes the standard care for stage Ⅱ/Ⅲ colon cancer. Recent advances in surgical conception and in understanding the biologic characteristics especially prognostic and predict biomarkers of colon cancer are expected to translate into individualized therapeutic strategies tailored to select patients. And with the success of perioperative treatment in rectal cancer, increasing concern is raised in the neoadjuvant chemotherapy of local advanced colon cancer. This article focuses on the advances in neoadjuvant and adjuvant therapy of colon cancer and we hope to assist the clinician to define the optimal perioperativet treatments for patients in routine clinical practice. Key words: Colon neoplasms; Adjuvant treatment; Neoadjuvant treatment
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call